Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?

Abstract

Cancer is a highly aggressive and devastating disease, and impediments to a cure arise not just from cancer itself. Targeted therapies are difficult to achieve since the majority of cancers are more intricate than ever imagined. Mainstream methodologies including chemotherapy and radiotherapy as routine clinical regimens frequently fail, eventually leading to pathologies that are refractory and incurable. One major cause is the gradual to rapid repopulation of surviving cancer cells during intervals of multiple-dose administration. Novel stress-responsive molecular pathways are increasingly unmasked and show promise as emerging targets for advanced strategies that aim at both de novo and acquired resistance. We highlight recent data reporting that treatments particularly those genotoxic can induce highly conserved damage responses in non-cancerous constituents of the tumor microenvironment (TMEN). Master regulators, including but not limited to NF-kB and C/EBP-β, are implicated and their signal cascades culminate in a robust, chronic and genome-wide secretory program, forming an activated TMEN that releases a myriad of soluble factors. The damage-elicited but essentially off target and cell non-autonomous secretory phenotype of host stroma causes adverse consequences, among which is acquired resistance of cancer cells. Harnessing signals arising from the TMEN, a pathophysiological niche frequently damaged by medical interventions, has the potential to promote overall efficacy and improve clinical outcomes provided that appropriate actions are ingeniously integrated into contemporary therapies. Thereby, anticancer regimens should be well tuned to establish an innovative clinical avenue, and such advancement will allow future oncological treatments to be more specific, accurate, thorough and personalized.

Key words： tumor microenvironment; DNA damage; secretory phenotype; therapy resistance; genotoxicity; clinical intervention

References

1 Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell133: 1006-1018

2 Alspach E, Flanagan KC, Luo X, Ruhland MK, Huang H, Pazolli E, Donlin MJ, Marsh T, Piwnica-Worms D, Monahan J, Novack DV, McAllister SS, Stewart SA (2014) p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov4: 716-729

3 Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J (2009) MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY)1: 402-411

4 Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol3: 932-943

5 Borodkina A, Shatrova A, Abushik P, Nikolsky N, Burova E (2014) Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging (Albany NY)6: 481-495

6 Bourzac K (2014) Biology: three known unknowns. Nature509: S69-S71

7 Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol75: 685-705

8 Campisi J (2014) Cell biology: the beginning of the end. Nature505: 35-36

9 Chandler H, Peters G (2013) Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol6: 765-771

10 Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW (2011) Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev25: 2125-2136

11 Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer10: 51-57

12 Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol6: 2853-2868

13 Coppe JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol5: 99-118

14 Coppé J-P, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J (2011) Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem286: 36396-36403

15 Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, Haber JE, Iliakis G, Kallioniemi OP, Halazonetis TD (2014) Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science343: 88-91

16 Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science339: 286-291

17 d'Adda di Fagagna F (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer8: 512-522

18 Davalos AR, Coppe JP, Campisi J, Desprez PY (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev29: 273-283

19 de Bono JS, Sandhu S, Attard G (2011) Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell19: 573-574

20 Freund A, Orjalo AV, Desprez PY, Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med16: 238-246

21 Freund A, Patil PK, Campisi J (2011) p38MAPK is a novel DNA damage response-independent regulator of the senescenceassociated secretory phenotype. EMBO J30: 1536-1548

22 Fumagalli M, d’Adda di Fagagna F (2009) SASPense and DDRama in cancer and ageing. Nat Cell Biol11: 921-923

23 Garber K (2013) PARP inhibitors bounce back. Nat Rev Drug Discov12: 725-727

24 Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell143: 355-366

25 Gilbert LA, Hemann MT (2011) Chemotherapeutic resistance: surviving stressful situations. Cancer Res71: 5062-5066

26 Goruppi S, Dotto GP (2013) Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol23: 593-602

27 Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci34: 508-517

28 Hallek M, Chen J, Hemann MT (2014) Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell156: 590-602

29 Harrison C (2013) Pharmacokinetics: single-cell imaging adds insight into drug action. Nat Rev Drug Discov12: 264

30 Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer8: 193-204

31 Helleday T, Eshtad S, Nik-Zainal S (2014) Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet15: 585-598

32 Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature461: 1071-1078

33 Junttila MR, de Sauvage FJ (2013) Influence of tumour microenvironment heterogeneity on therapeutic response. Nature501: 346-354

34 Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell141: 52-67

35 Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer5: 516-525

36 Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön MP, Dobbelstein M (2013) Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci USA110: 16856-16861

37 Kuilman T, Peeper DS (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer9: 81-94

38 Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS (2008) Oncogeneinduced senescence relayed by an interleukin-dependent inflammatory network. Cell133: 1019-1031

39 Liu D, Hornsby PJ (2007) Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res67: 3117-3126

40 Moiseeva O, Deschênes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell12: 489-498

41 Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer9: 274-284

42 Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep70: 163-169

43 Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari L, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C (2011) Senescent cells develop a PARP-1 and nuclear factor-êB-associated secretome (PNAS). Genes Dev25: 1245-1261

44 Orjalo A, BhaumikD Gengler B, ScottGK Campisi J (2009) Cell surface IL-1α is an upstream regulator of the senescenceassociated IL-6/IL-8 cytokine network. Proc Natl Acad Sci USA106: 17031-17036

45 Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell25: 719-734

46 Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Palucka K, Banchereau J (2014) SnapShot: cancer vaccines. Cell157: 516

47 Palucka K, Banchereau J (2014) SnapShot: cancer vaccines. Cell157: 516-516

48 Patel KJ, Lee C, Tan Q, Tannock IF (2013) Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res19: 6766-6776

49 Pulukuri SMK, Knost JA, Estes N, Rao JS (2009) Small interfering RNA-directed knockdown of uracil DNA glycosylase induces apoptosis and sensitizes human prostate cancer cells to genotoxic stress. Mol Cancer Res7: 1285-1293

50 Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell25: 735-747

51 Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol.11: 973-979

52 Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, Coppé JP, Campeau E, Beauséjour CM, Kim SH, Davalos AR, Campisi J (2011) DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci124: 68-81

53 Sale JE, Lehmann AR, Woodgate R (2012) Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol13: 141-152

54 Schmitt CA (2003) Senescence, apoptosis and therapy—cutting the lifelines of cancer. Nat Rev Cancer3: 286-295

55 Sun Y, Nelson PS (2012) Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 18: 4019-4025

56 Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med18: 1359-1368

57 Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PNAS103: 12481-12486

58 Tell G, Wilson DM III (2010) Targeting DNA repair proteins for cancer treatment. Cell Mol Life Sci67: 3569-3572

59 Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G (2010) Pharmacological inhibition of poly(ADPribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. Curr Cancer Drug Targets 10: 368-383

60 Tomé M, Sepúlveda JC, Delgado M, Andrades JA, Campisi J, González MA, Bernad A (2014) MiR-335 correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions through inhibition of AP-1 activity. Stem Cells32: 2299-2344

61 Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer8: 755-768

62 Wang Z, Chen W (2013) Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer4: 82-90

63 Yu M, Tannock IF (2012) Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell21: 327-329

64 Yu M, Ocana A, Tannock IF (2013) Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev32: 211-227